KBC Group NV Has $57,000 Holdings in Certara, Inc. (NASDAQ:CERT)

KBC Group NV boosted its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 48.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,873 shares of the company’s stock after buying an additional 1,584 shares during the quarter. KBC Group NV’s holdings in Certara were worth $57,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of CERT. Geneva Capital Management LLC lifted its position in Certara by 0.7% during the 3rd quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock worth $64,525,000 after acquiring an additional 37,392 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Certara by 9.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock worth $42,643,000 after purchasing an additional 273,095 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Certara by 9.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,773,892 shares of the company’s stock worth $38,418,000 after acquiring an additional 248,448 shares in the last quarter. Daventry Group LP increased its stake in shares of Certara by 153.0% in the second quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock valued at $18,124,000 after buying an additional 791,405 shares in the last quarter. Finally, Sei Investments Co. lifted its position in shares of Certara by 39.5% during the second quarter. Sei Investments Co. now owns 997,871 shares of the company’s stock worth $13,821,000 after purchasing an additional 282,357 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Stock Up 6.0 %

Shares of CERT opened at $10.36 on Friday. The firm has a market cap of $1.67 billion, a P/E ratio of -51.80, a price-to-earnings-growth ratio of 4.94 and a beta of 1.51. The firm’s 50-day simple moving average is $10.79 and its 200 day simple moving average is $13.19. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.87.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to analysts’ expectations of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.06 earnings per share. On average, analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current year.

Insider Transactions at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the transaction, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This represents a 33.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. The trade was a 9.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Friday, September 27th. Barclays lowered their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Finally, Robert W. Baird lowered their price target on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $15.92.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.